Phathom Pharmaceuticals (PHAT) Competitors $3.90 -0.48 (-10.96%) Closing price 04:00 PM EasternExtended Trading$3.78 -0.12 (-2.95%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAT vs. PHVS, ARDX, ZYME, LENZ, CVAC, CRMD, CMRX, CDMO, CRON, and PRAXShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include Pharvaris (PHVS), Ardelyx (ARDX), Zymeworks (ZYME), LENZ Therapeutics (LENZ), CureVac (CVAC), CorMedix (CRMD), Chimerix (CMRX), Avid Bioservices (CDMO), Cronos Group (CRON), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Phathom Pharmaceuticals vs. Pharvaris Ardelyx Zymeworks LENZ Therapeutics CureVac CorMedix Chimerix Avid Bioservices Cronos Group Praxis Precision Medicines Pharvaris (NASDAQ:PHVS) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership. Which has stronger earnings and valuation, PHVS or PHAT? Pharvaris has higher earnings, but lower revenue than Phathom Pharmaceuticals. Pharvaris is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharvarisN/AN/A-$109.18M-$3.01-5.58Phathom Pharmaceuticals$81.86M3.21-$201.59M-$5.24-0.72 Is PHVS or PHAT more profitable? Pharvaris has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets PharvarisN/A -38.52% -36.69% Phathom Pharmaceuticals -1,292.14%N/A -79.57% Which has more risk & volatility, PHVS or PHAT? Pharvaris has a beta of -2.85, suggesting that its stock price is 385% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Do institutionals & insiders have more ownership in PHVS or PHAT? 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 11.8% of Pharvaris shares are held by company insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer PHVS or PHAT? Pharvaris presently has a consensus target price of $40.67, suggesting a potential upside of 142.12%. Phathom Pharmaceuticals has a consensus target price of $17.60, suggesting a potential upside of 367.46%. Given Phathom Pharmaceuticals' higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Pharvaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in PHVS or PHAT? Phathom Pharmaceuticals received 62 more outperform votes than Pharvaris when rated by MarketBeat users. Likewise, 72.46% of users gave Phathom Pharmaceuticals an outperform vote while only 67.86% of users gave Pharvaris an outperform vote. CompanyUnderperformOutperformPharvarisOutperform Votes3867.86% Underperform Votes1832.14% Phathom PharmaceuticalsOutperform Votes10072.46% Underperform Votes3827.54% Does the media prefer PHVS or PHAT? In the previous week, Pharvaris had 20 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 22 mentions for Pharvaris and 2 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.08 beat Pharvaris' score of 0.33 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Phathom Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPhathom Pharmaceuticals beats Pharvaris on 12 of the 17 factors compared between the two stocks. Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$262.50M$6.51B$5.38B$8.42BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.668.9726.6219.77Price / Sales3.21253.27392.02116.56Price / CashN/A65.8538.2534.62Price / Book-2.966.486.814.53Net Income-$201.59M$143.98M$3.23B$248.18M7 Day Performance15.85%3.37%4.05%1.06%1 Month Performance-3.46%7.83%11.64%14.68%1 Year Performance-64.91%-2.24%17.11%6.87% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals3.8864 of 5 stars$3.90-11.0%$17.60+351.3%-59.8%$272.28M$81.86M-0.69110Positive NewsGap DownPHVSPharvaris1.2803 of 5 stars$16.81-1.1%$41.67+147.9%-16.5%$879.00MN/A-6.0030ARDXArdelyx4.4986 of 5 stars$3.53-2.5%$10.39+194.3%-47.3%$844.57M$361.71M-22.0690Insider TradeZYMEZymeworks3.5197 of 5 stars$12.02+6.3%$21.00+74.7%+38.4%$836.32M$76.30M-8.01460News CoveragePositive NewsAnalyst ForecastInsider TradeLENZLENZ Therapeutics1.887 of 5 stars$29.37+11.5%$46.60+58.7%+54.5%$826.65MN/A-16.59110CVACCureVac3.7187 of 5 stars$3.62+4.3%$14.00+286.7%+25.9%$812.10M$535.18M6.58880News CoverageUpcoming EarningsGap DownCRMDCorMedix2.1004 of 5 stars$11.86+1.7%$15.00+26.5%+153.9%$804.40M$82.55M-14.6430Positive NewsCMRXChimerix0.5614 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990Analyst ForecastCDMOAvid Bioservices0.8126 of 5 stars$12.50+0.1%$12.25-2.0%+34.6%$799.18M$139.91M-5.23320High Trading VolumeCRONCronos Group1.015 of 5 stars$2.05+3.5%$3.50+70.7%-24.8%$790.08M$117.62M-15.77450Positive NewsHigh Trading VolumePRAXPraxis Precision Medicines3.1765 of 5 stars$38.42+0.2%$116.50+203.2%-11.8%$782.58M$8.12M-3.73110Positive News Related Companies and Tools Related Companies Pharvaris Alternatives Ardelyx Alternatives Zymeworks Alternatives LENZ Therapeutics Alternatives CureVac Alternatives CorMedix Alternatives Chimerix Alternatives Avid Bioservices Alternatives Cronos Group Alternatives Praxis Precision Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHAT Stock Free PHAT Stock Alerts